Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2020 Mar 13

PMID 32161990

Citations 997

Authors

Bo Li

Jing Yang

Faming Zhao

Lili Zhi

Xiqian Wang

Lin Liu

Zhaohui Bi

Yunhe Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.

Methods: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.

Results: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.

Conclusion: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart.

Citing Articles

Violence against healthcare workers in Kenya: a cross-sectional sub-analysis of the global vishwas study.

Shah R, Shah J, Qasba R, Qasba R, Mbithi A, Njenga E BMC Public Health. 2025; 25(1):938.

PMID: 40065291 PMC: 11892256. DOI: 10.1186/s12889-024-20753-w.

Correlation of diabetes and adverse outcomes in hospitalized COVID-19 patients admitted to a tertiary hospital in China during a small-scale COVID-19 outbreak.

Li Y, Li G, Li J, Luo Z, Lin Y, Lan N PeerJ. 2025; 13:e18865.

PMID: 39886017 PMC: 11781264. DOI: 10.7717/peerj.18865.

An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies.

AlTaweel M, Almusaad A, Alkhazmari G, Alrowaily H, Alsubaiee M, Husain M Arch Microbiol Immunol. 2024; 8(3):290-308.

PMID: 39703820 PMC: 11658003. DOI: 10.26502/ami.936500177.

Pathological Sequelae of SARS-CoV-2: A Review for Clinicians.

Nyarko J, Dogbe P, Ativi L, Wutsika J, Agyenim E, Awere-Duodu A Yale J Biol Med. 2024; 97(4):431-445.

PMID: 39703609 PMC: 11650917. DOI: 10.59249/DQJH2274.

Healthcare access, attitudes and behaviours among Navajo adults during the COVID-19 pandemic: a cross-sectional study.

Brown H, Begay R, Sanderson P, Chief C, Lameman B, Harris R BMJ Public Health. 2024; 2(1).

PMID: 39669294 PMC: 11636652. DOI: 10.1136/bmjph-2023-000061.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Yu C, Wong R, Wu E, Kong S, Wong J, Yip G . Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006; 82(964):140-4. PMC: 2596695. DOI: 10.1136/pgmj.2005.037515. View

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz C . Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA. 2020; 323(11):1092-1093. PMC: 7042871. DOI: 10.1001/jama.2020.1623. View

Badawi A, Ryoo S . Prevalence of Diabetes in the 2009 Influenza A (H1N1) and the Middle East Respiratory Syndrome Coronavirus: A Systematic Review and Meta-Analysis. J Public Health Res. 2017; 5(3):733. PMC: 5206772. DOI: 10.4081/jphr.2016.733. View

Yang J, Feng Y, Yuan M, Yuan S, Fu H, Wu B . Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006; 23(6):623-8. DOI: 10.1111/j.1464-5491.2006.01861.x. View

Oudit G, Kassiri Z, Jiang C, Liu P, Poutanen S, Penninger J . SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009; 39(7):618-25. PMC: 7163766. DOI: 10.1111/j.1365-2362.2009.02153.x. View

Badawi A, Ryoo S . Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016; 49:129-33. PMC: 7110556. DOI: 10.1016/j.ijid.2016.06.015. View

10.

Chan J, Ng C, Chan Y, Mok T, Lee S, Chu S . Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003; 58(8):686-9. PMC: 1746764. DOI: 10.1136/thorax.58.8.686. View

11.

Greenland S . Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987; 9:1-30. DOI: 10.1093/oxfordjournals.epirev.a036298. View

12.

Liu K, Fang Y, Deng Y, Liu W, Wang M, Ma J . Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020; 133(9):1025-1031. PMC: 7147277. DOI: 10.1097/CM9.0000000000000744. View

13.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G . The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res. 2016; 105:74-83. DOI: 10.1016/j.phrs.2016.01.005. View

14.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

15.

Su S, Wong G, Shi W, Liu J, Lai A, Zhou J . Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016; 24(6):490-502. PMC: 7125511. DOI: 10.1016/j.tim.2016.03.003. View

16.

Chan K, Zheng J, Mok Y, Li Y, Liu Y, Chu C . SARS: prognosis, outcome and sequelae. Respirology. 2004; 8 Suppl:S36-40. PMC: 7169213. DOI: 10.1046/j.1440-1843.2003.00522.x. View

17.

Cui J, Li F, Shi Z . Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2018; 17(3):181-192. PMC: 7097006. DOI: 10.1038/s41579-018-0118-9. View

18.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

19.

Li F, Li W, Farzan M, Harrison S . Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742):1864-8. DOI: 10.1126/science.1116480. View

20.

Stewart L, Clarke M, Rovers M, Riley R, Simmonds M, Stewart G . Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015; 313(16):1657-65. DOI: 10.1001/jama.2015.3656. View